Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Lornoxicam

A Short Half-life Oxicam

  • Review Article
  • Drug Disposition
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Lornoxicam (chlorotenoxicam) is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class. Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours). Lornoxicam is eliminated following biotransformation to 5′-hydroxy-lornoxicam, which does not undergo enterohepatic recirculation. Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours.

Lornoxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of lornoxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. The effects of lornoxicam concentration on its therapeutic and toxicological properties have not yet been extensively reported. Lornoxicam, like other NSAIDs, appears to interact with warfarin, sulphonylureas, digoxin and furosemide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Balfour JA, Fitton A, Barradell LB. Lornoxicam: a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51 (4): 639–57.

    Article  PubMed  CAS  Google Scholar 

  2. Pruss TP, Stroissnig H, Radhofer-Welte S, et al. Overview of the pharmacological properties, pharmacokinetics and animal safety assessment of lornoxicam. Postgrad Med J 1990; 66 Suppl. 4: S18–21.

    Google Scholar 

  3. Stiernieri E, Bussone G, Manzoni GC. Lornoxicam, a new nonsteroidal anti-inflammatory drug, in migraine prophylaxis: double-blind multicenter study. Cephalalgia 1991; 11 Suppl. 11: 154–5.

    Google Scholar 

  4. Dittrich P, Ferber HP, Kukovetz WR. Determination of chlortenoxicam, a novel nonsteroidal anti-inflammatory drug in human plasma [abstract P573]. 10th International Congress of Pharmacology: 1987 Aug 23–8; Sydney.

    Google Scholar 

  5. Suwa T, Urano H, Shinohara Y, et al. Simultaneous high-performance liquid Chromatographic determination of lornoxicam and its 5′-hydroxy metabolite in human plasma using electrochemical detection. J Chromatogr B Biomed Appl 1993; 617: 105–10.

    Article  CAS  Google Scholar 

  6. Hitzenberger G, Radhofer-Welte S, Takacs F, et al. Pharmacokinetics of lornoxicam in man. Postgrad Med J 1990; 66 Suppl. 4: S2–6.

    Google Scholar 

  7. Ankier SI, Brimelow AE, Crome P, et al. Chlortenoxicam pharmacokinetics in young and elderly human volunteers. Postgrad Med J 1988; 64: 752–4.

    Article  PubMed  CAS  Google Scholar 

  8. Dittrich P, Radhofer-Welte S, Mayerhofer S, et al. Comparative pharmacokinetics of parenteral lornoxicam [abstract]. Eur J Pharmacol 1990; 183: 2265–6.

    Article  Google Scholar 

  9. Ravic M, Johnston A, Turner P. Clinical pharmacological studies of some possible Interactions of lornoxicam with other drugs. Postgrad Med J 1990; 66: Suppl. 4: S30–4.

    PubMed  Google Scholar 

  10. Turner P, Johnston A. Clinical pharmacokinetic studies with lornoxicam. Postgrad Med J 1990; 66 Suppl. 4: S28–9.

    Google Scholar 

  11. Ravic M, Johnston A, Turner P, et al. The effect of repeated oral doses of lornoxicam on antipyrine elimination in normal human volunteers. Hum Exp Toxicol 1991; 10: 375–7.

    Article  PubMed  CAS  Google Scholar 

  12. Ravic M, Johnston A, Turner P, et al. Does bismuth chelate influence lornoxicam absorption? [letter]. Hum Exp Toxicol 1992; 11: 59–60.

    Article  PubMed  CAS  Google Scholar 

  13. Ravic M, Salas-Herrera I, Johnston A, et al. Influence of lornoxicam a new non-steroidal anti-inflammatory drug on lithium pharmacokinetics. Hum Psychopharm 1993; 8: 289–92.

    Article  CAS  Google Scholar 

  14. Ravic M, Salas-Herrera I, Johnston A, et al. A pharmacokinetic interaction between cimetidine or ranitidine and lornoxicam. Postgrad Med J 1993; 69: 865–6.

    Article  PubMed  CAS  Google Scholar 

  15. Dittrich P, Radhofer-Welte S, Magometschnigg D, et al. The effect of concomitantly administered antacids on the bioavailability of lornoxicam, a novel highly potent NSAID. Drys Exp Clin Res 1990; 16 (2): 57–62.

    CAS  Google Scholar 

  16. Mayerhofer S, Welte S, Magometschnigg D, et al. The effect of food on pharmacokinetic parameters of the new NSAID lornoxicam in healthy volunteers [abstract]. 3rd Interscience World Conference on Inflammation, Antirheumatics, Analgesics and Immunimodulators: 1989 Mar 15–8; Monte Carlo.

    Google Scholar 

  17. Bareggi SR, Gambaro V, Valenti M, et al. Absorption of oral lornoxicam in healthy volunteers using a granular formulation in comparison with standard tablets. Arzneimettel Forschung 1997; 47 (1): 755–7.

    CAS  Google Scholar 

  18. Olkkola KT, Brunetto AV, Matilla MJ. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents. Clin Pharmacokinet 1994; 26: 107–20.

    Article  PubMed  CAS  Google Scholar 

  19. Albengres W, Urien S, Barre J, et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dosedependent toxicity. Int J Tissue React 1993; 15 (3): 125–34.

    PubMed  CAS  Google Scholar 

  20. Leeman TD, Transon C, Bonnabry P, et al. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 1993; 19: 189–95.

    Google Scholar 

  21. Bonnabry P, Leeman T, Dayer P. Role of human liver cytochrome cytochrome P450TB (CYP2C subfamily) in the biotransformation of lornoxicam. Clin Pharmacol Ther 1996; 49: 305–8.

    CAS  Google Scholar 

  22. Davies NM, Anderson KE. Clinical pharmacokinetics of diclofenac: therapeutic insights and pitfalls. Clin Pharmacokinet 1997; 33 (3): 184–213.

    Article  PubMed  CAS  Google Scholar 

  23. Reuter BK, Davies NM, Wallace JL. NSAID-enteropathy in rats: role of epithelial permeability, bacterial load, and enterohepatic circulation. Gastroenterology 1997; 112 (1): 109–17.

    Article  PubMed  CAS  Google Scholar 

  24. Ravic M, Johnston A, Turner P, et al. A study of the interaction between lornoxicam and warfarin in healthy volunteers. Hum Exp Toxicol 1990; 9: 413–4.

    Article  PubMed  CAS  Google Scholar 

  25. Hitoglou-Makedou A, Lawson M, Turner P, et al. Comparison of chlortenoxicam and indomethacin on furosemide-induced diuresis. Postgrad Med J 1989; 65: 821–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Calgary, Calgary, Alberta, Canada

    Neil M. Skjodt

  2. Department of Pharmacology and Therapeutics, Intestinal Disease Research Unit, Faculty of Medicine, University of Calgary, Calgary, Alberta, T2N 4N1, Canada

    Neal M. Davies

Authors
  1. Neil M. Skjodt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neal M. Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neal M. Davies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skjodt, N.M., Davies, N.M. Clinical Pharmacokinetics of Lornoxicam. Clin Pharmacokinet 34, 421–428 (1998). https://doi.org/10.2165/00003088-199834060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199834060-00001

Keywords

Search

Navigation